Evaluation of estrogen therapy on the height of children with chronic kidney disease
Phase 3
- Conditions
- Short stature.Disorders resulting from impaired renal tubular function
- Registration Number
- IRCT20201110049334N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 75
Inclusion Criteria
Patient and parent consent to participate in the study.
Patients with chronic kidney disease (CKD).
Patients must be girls.
With short stature (height and growth velocity respectively below 3th and 25th percentile for more than 1 year).
In all patients, beginning of dialysis around 3.5 to 5 years.
Growth hormone has been started in all patients from the age of 5.5 to 8 years, despite therapeutic indications.
Exclusion Criteria
Incidence puberty before the estrogen therapy
Kidney transplantation before the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Final height after 15 years old. Timepoint: Before the intervention and after the age of 15. Method of measurement: Height gauge.
- Secondary Outcome Measures
Name Time Method Bone density. Timepoint: Before the intervention and after the age of 15. Method of measurement: Dexa bone densitometry.